NICE Guidance - May 2023
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of May 2023. This month are three guidelines and two health technology evaluations that impact upon primary care.
The Cardiovascular disease: risk assessment and reduction, including lipid modification guideline has been updated. It covers the assessment and care of adults who are at risk of or who have cardiovascular disease. This update now recommends use of the QRISK3 prediction tool. The recommendations about cardioprotective diets and statin treatment for primary and secondary prevention have been reviewed. The threshold for considering treatment has remained at a 10‑year risk of CVD is 10% or more.
The Acne vulgaris: management guideline and been updated. It covers the management of acne vulgaris in primary and specialist care. The updated included recent safety updates including recommendations to strengthen the safety of isotretinoin treatment.
The Diabetes (type 1 and type 2) in children and young people: diagnosis and management guideline has been updated. It covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The update made new recommendations on blood glucose monitoring and management.
The Digitally enabled therapies for adults with depression and the Digitally enabled therapies for adults with anxiety disorders early value assessments have been published. Three and six digitally enabled therapies are respectively recommended as treatment options. It is recommended that where these options are used, further evidence is generated on their clinical and cost effectiveness.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
| « SMC Update - May 2023 | Drug Safety Update - May 2023 » |
Leave a Comment